SARS-CoV-2 Omicron variant binding to its receptor and therapeutic entities

In a recent study posted to the bioRxiv* preprint server, a team of researchers generated a set of computed structural models of the Omicron receptor-binding domain (omRBD) attached to its receptor angiotensin-converting enzyme (ACE2). In addition, they modeled several neutralizing and therapeutic antibodies targeting other severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains.

Study: Structural models of SARS-CoV-2 Omicron variant in complex with ACE2 receptor or antibodies suggest altered binding interfaces. Image Credit: Kateryna Kon/ShutterstockStudy: Structural models of SARS-CoV-2 Omicron variant in complex with ACE2 receptor or antibodies suggest altered binding interfaces. Image Credit: Kateryna Kon/Shutterstock

Omicron (B.1.1.529), the most recently identified variant of concern (VOC) of SARS-CoV-2, is currently spreading within the human population worldwide. However, the approximately 15 mutations in the omRBD of the spike (S) protein most likely responsible for its increased virulence, transmissibility, and susceptibility to neutralizing antibodies are barely known.

*Important notice: bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

About the study

The researchers modeled omRBD with its ACE2 and various therapeutic entities using both experimentally determined structures of S-TE interactions (of previous SARS-CoV-2 variants) and artificial intelligence/machine learning (AI/ML)-structure predictions as starting points. In total, there were 388 therapeutic entities (TEs), multi-protein complex structures, atomic-level structures for which are archived in the Protein Data Bank (PDB) and were freely available. There were 286 unique bound polypeptides TEs, and some even had more than one distinct polypeptide.

The researchers pursued antibodies from all four Barnes Classes, including a REGEN-COV cocktail and S309 therapeutic antibodies. SARS-CoV-2 antibodies have been divided into four Barnes classes, depending on how their binding sites overlap with the ACE2-binding site and access RBD. A cocktail is two or more unique bound proteins in a single multi-protein complex.

The selection criteria for a given PDB ID were that it should have an antibody with high resolution, resolved residues in and near the S-binding site, no S-mutations, and contains only intended antibody (not a cocktail). In total, 20 out of 236 unique S-bound antibodies were selected from the PDB as representative cases of RBD-binding antibodies for detailed analysis in the context of the Omicron VOC.

Results

The researchers curated all SARS-CoV-2 spike structures in the PDB, including 388 distinct S-TE complexes. They listed bound proteins/peptides or each PDB ID and, if it was a cocktail, specifically by polypeptide chain(s). 

Alterations in individual Spike-TE interface topologies and a large-scale analysis of these computed protein-protein complexes provided insights into the molecular basis for their attenuated immune response, suggested possibilities for the redesign of TEs (e.g., antibody cocktails) as effective countermeasures against the Omicron VOC.

Analyses of synonymous and non-synonymous mutations in the omRBD, compared to other SARS-CoV-2 VOCs, indicated that several of these substitutions clustered in a single binding region have likely undergone positive selection, suggesting that these mutations were beneficial to the virus.

Subsequently, Omicron RBD-ACE2 binding was robust, as indicated by the emergence of a multi-residue network of interactions. Further analysis showed that binding between omRBD and Class 1 and Class 2 antibodies was slightly altered due to the domination of destabilizing interactions over stabilizing interactions arising from the numerous substitutions in the Omicron VOC. On the other hand, interaction networks in Class 3 and Class 4 antibodies such as S309 and CR3022, respectively, appeared only moderately affected or unaltered.

Conclusions

To conclude, the present study has organized SARS-CoV-2 spike structures available in PDB to generate computational models of omRBD complexes with ACE2 and a diverse set of antibodies from all four Barnes Classes. These models showed strikingly altered Spike-TE interfaces that helped researchers derive qualitative inferences about the energetic impact of substituted residues at the interfaces and provide hypotheses regarding their effects on the structural remodeling of interactions.

The structure models of omRBD complexes and large-scale analyses of S interfaces of Omicron VOC will bolster research efforts worldwide to aid the global community’s response to the SARS-CoV-2 pandemic. 

The data of all the computed structural models, including an initial set of 38 complexes of 20 binding entities, is available online for the broad scientific community to complement ongoing research of the Omicron VOC. This data and models could provide visual aids plus testable hypotheses to wet laboratory investigators trying to characterize the impact of individual or clusters of omRBD substitutions observed in omRBD and develop a better understanding of the efficacy of immune response against the Omicron VOC. 

In cases where the binding of therapeutic antibodies is functionally compromised, these models could provide starting points for computer-aided antibody design efforts and molecular level insights into ligand-directed 3D recognition of omRBD by various binding proteins and TEs. In the future, research studies should aim at generating more such models based on other complex structures available in the PDB.

*Important notice: bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:
  • Preliminary scientific report.

    Lubin, J. et al. (2021) "Structural models of SARS-CoV-2 Omicron variant in complex with ACE2 receptor or antibodies suggest altered binding interfaces". bioRxiv. doi: doi.org/10.1101/2021.12.12.472313

Neha Mathur

Written by

Neha Mathur

Neha is a digital marketing professional based in Gurugram, India. She has a Master’s degree from the University of Rajasthan with a specialization in Biotechnology in 2008. She has experience in pre-clinical research as part of her research project in The Department of Toxicology at the prestigious Central Drug Research Institute (CDRI), Lucknow, India. She also holds a certification in C++ programming.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mathur, Neha. (2023, January 18). SARS-CoV-2 Omicron variant binding to its receptor and therapeutic entities. News-Medical. Retrieved on November 24, 2024 from https://www.news-medical.net/news/20211215/SARS-CoV-2-Omicron-variant-binding-to-its-receptor-and-therapeutic-entities.aspx.

  • MLA

    Mathur, Neha. "SARS-CoV-2 Omicron variant binding to its receptor and therapeutic entities". News-Medical. 24 November 2024. <https://www.news-medical.net/news/20211215/SARS-CoV-2-Omicron-variant-binding-to-its-receptor-and-therapeutic-entities.aspx>.

  • Chicago

    Mathur, Neha. "SARS-CoV-2 Omicron variant binding to its receptor and therapeutic entities". News-Medical. https://www.news-medical.net/news/20211215/SARS-CoV-2-Omicron-variant-binding-to-its-receptor-and-therapeutic-entities.aspx. (accessed November 24, 2024).

  • Harvard

    Mathur, Neha. 2023. SARS-CoV-2 Omicron variant binding to its receptor and therapeutic entities. News-Medical, viewed 24 November 2024, https://www.news-medical.net/news/20211215/SARS-CoV-2-Omicron-variant-binding-to-its-receptor-and-therapeutic-entities.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Inequities in COVID-19 vaccination coverage for older adults highlighted in global study